安科生物：LV009预计半个月后会进入疗效评估阶段

Core Viewpoint - Anke Bio (300009) is advancing its participation in the CAR-T therapy development through its affiliate, Boshengji, which has initiated a dose escalation plan for its LV009 product and is currently enrolling patients for clinical trials [1] Group 1 - Anke Bio's affiliate, Boshengji, has completed the design for the accelerated dose escalation scheme for its In vivo CAR-T LV009 [1] - The first patient has been enrolled in the clinical trial, with efficacy evaluation expected to begin in approximately two weeks [1] - Boshengji is simultaneously screening additional patients and has initiated ethical reviews at three hospitals to support IND application and business development data acquisition [1]